JR023-5

General

Cell Line

hPSCreg name UOXFi010-C
Cite as:
UOXFi010-C (RRID:CVCL_LE48)
Alternative name(s)
JR023-5
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
UOXFi010-A
(JR023-1)
Donor diseases:
Parkinson disease
UOXFi010-B
(JR023-2)
Donor diseases:
Parkinson disease
UOXFi010-D
(JR023-7)
Donor diseases:
Parkinson disease
LCSBi012-A-1
(RHOT1_T610A_clone62.19.37_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi008-A-1
(delP GC13, DJ-1-delP GC13)
Donor diseases:
Parkinson Disease
SUSMi005-A-1
(SNCA3X 0KO C1, SNCA3X 0KO C2)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-2
(SNCA3X 1KO C2, SNCA3X 1KO C1)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-3
(SNCA3X 2KO C1, SNCA3X 2KO C2)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-4
(SNCA3X 3KO C1, SNCA3X 3KO C2)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-5
(SNCA3X 4KO C1, SNCA3X 4KO C2)
Donor diseases:
obsolete_Parkinson's disease
LCSBi011-A-1
(RHOT1_T351A_clone25.2_IsogenicControl)
Donor diseases:
Parkinson Disease
EDi001-A-1
(AST22-C, AST23-C)
Donor's gene variants:
SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-2
(AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-3
(AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-4
(AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
UOXFi003-A
(MK088-1)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi003-C
(MK088-7)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
MPIi003-A-1
(IM2GC, L2-2GC)
Donor diseases:
obsolete_Parkinson's disease
EDi001-B-1
(AST18-7A)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-B-2
(AST18-7B)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-B-3
(AST18-5D)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-B-4
(AST18-6A)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-A-5
(AST23-2KO-II8B)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi004-B-1
(SFC832-03-06 LRRK2WT/WT C47)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
FINi002-A
(FI.CPLT.PRKN.R275W+del_e8.PK006)
Donor's gene variants:
PRKN
Donor diseases:
Parkinson Disease
LCSBi009-A-1
(RHOT1_R272Q_clone18_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi010-A-1
(RHOT1_R450C_clone6_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi010-A-2
(RHOT1_R450C_clone10_IsogenicControl)
Donor diseases:
Parkinson Disease
SHEHDNi002-A
(KY03AP)
Donor's gene variants:
LRRK2, DNAJC6
Donor diseases:
Parkinson Disease
EDi001-A
(AST22, AST23, SAMEA3319992)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
UOXFi001-A
(MK071-1)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi001-B
(MK071-3)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi001-C
(MK071-5)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi001-D
(MK071-6)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
EDi001-B
(AST18)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
UOXFi007-A
(MK002-4)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
UOXFi008-A
(MK144-1)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
ICGi015-B-1
(m6.7pCyto-17)
Donor diseases:
Parkinson Disease
ICGi015-B-2
(m6.7pCyto-21)
Donor diseases:
Parkinson Disease
ICGi015-B-3
(m6.7pCyto-24)
Donor diseases:
Parkinson Disease
UKERi002-A
(UKERiM89-R1-006)
Donor diseases:
obsolete_Parkinson's disease
UKERi003-A
(UKERiPX7-R1-001)
Donor diseases:
obsolete_Parkinson's disease
ICGi034-A-1
(PD30-XBP-RFP-6, PD30-4-7-XBP-RFP-6)
Donor diseases:
obsolete_Parkinson's disease
ICGi034-A-2
(PD30-4-7-XBP-RFP-51, PD30-XBP-RFP-51)
Donor diseases:
obsolete_Parkinson's disease
PNUSCRi002-A
(GBA PD iPSC9)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
ICGi042-A
(PD12-4Lm)
Donor's gene variants:
LRRK2, PINK1
Donor diseases:
Parkinson Disease
ICGi042-B
(PD12-5Lm)
Donor's gene variants:
LRRK2, PINK1
Donor diseases:
Parkinson Disease
STBCi090-B
(SFC867-04-12)
Donor diseases:
Parkinson disease
PNUSCRi001-A
(GBA PD iPSC7)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
LCSBi008-A
(delP, DJ-1-delP)
Donor diseases:
Parkinson Disease
Last update 27th January 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator University of Oxford (UOXF)
Distributors

External Databases

BioSamples SAMEA103887560
Cellosaurus CVCL_LE48
EBiSC UOXFi010-C
Wikidata Q54991541

General Information

Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 55-59

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Sporadic
The donor is affected.
Synonyms
  • Parkinson disease
  • Parkinson's disease
  • paralysis agitans

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA103887556

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Contact information / weblink Michele Hu
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Parkinson’s and related degenerative conditions.
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
Does consent expressly permit collection of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
How may genetic information associated with the cell line be accessed? Open Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Berkshire Research Ethics Committee
Approval number 10/H0505/71
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Berkshire Research Ethics Committee
Approval number 10/H0505/71
Do you have obligations to third parties in regard to the use of the cell line? Yes
Please describe: The cells are to be used in future research studies into Parkinson’s and related degenerative conditions.
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Any skin fibroblast that is part of some dermis.
Source cell origin
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
  • portion of skin
  • region of skin
  • skin
  • skin region
  • skin zone
show more synonyms
Age of donor (at collection) 55-59
Collected in 2010
Passage number reprogrammed 4

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Genes
Is the used vector excisable?
Unknown
Absence of reprogramming vector(s)?
Unknown
Reprogramming vectors silenced?
Yes
Methods used
RT-PCR

Vector free reprogramming

Other

Selection criteria for clones Morphology
Derived under xeno-free conditions
Yes
Derived under GMP?
Yes
Available as clinical grade?
Yes

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Supplements
ROCK inhibitor Y27632 10µM final concentration µM
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Pluripotency Score Novelty Score
21.12 1.68
Morphology pictures

Microbiology / Virus Screening

Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage:

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46XY
Passage number: 10
Karyotyping method: Molecular karyotyping by SNP array
http://

Other Genotyping (Cell Line)